

Table 4 Medical interventions for snakebite patients, Saudi Arabia, January 2000 to December 2021

Medical intervention	Frequency No. (%)
Antivenom administration	65 (94.2)
Antivenom dose, mean 14 (range 5–12.25)	
Neurological manifestations, mean 22.25 (range 8.75–31.5)	
Haematological manifestations, mean 19 (range 5–25)	
Compartment suspicious, mean 15 (range 5.5–12)	
Re-administration of antivenom	
No. of re-administrations	27 (39.1)
Swelling/compartment	15 (21.7)
Coagulopathy	6 (8.7)
Neurogenic	3 (4.3)
Other	3 (4.3)
Not applicable	11 (15.9)
Reaction to antivenom	
Managed antivenom reaction	6 (8.7)
Reaction severity	
None	62 (89.9)
Mild	5 (7.2)
Severe	1 (1.4)
Fasciotomy	11 (15.9)
Anti-cholinesterase	3 (4.3)
Anti-cholinesterase side effects	1 (1.4)
Prior atropine	2 (2.9)
Blood products	23 (33.3)
Opioid for pain management	9 (13.0)
Tetanus	7 (10.1)
Steroid	12 (17.4)
Antibiotics	46 (66.7)
Disposition	
Discharged against medical advice	6 (8.8)
Fatality	3 (4.5)
Discharged	57 (82.9)
Left against medical advice	3 (3.8)
Length of hospital stay, mean 3 (range 1–6.5)	
Neurogenic complication, mean 6 (range 1.5–7.5)	
Hematologic complication, mean 7 (range 3–7)	
Suspected compartment complication, mean 15 (range 6–22)	